Next Article in Journal
Prognostic Significance of Glucocorticoid Receptor Expression in Cancer: A Systematic Review and Meta-Analysis
Next Article in Special Issue
Dual Role of TNF and LTα in Carcinogenesis as Implicated by Studies in Mice
Previous Article in Journal
Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review
Previous Article in Special Issue
Loss of cIAP1 in Endothelial Cells Limits Metastatic Extravasation through Tumor-Derived Lymphotoxin Alpha
 
 
Article

Death Receptor 5 (TNFRSF10B) Is Upregulated and TRAIL Resistance Is Reversed in Hypoxia and Normoxia in Colorectal Cancer Cell Lines after Treatment with Skyrin, the Active Metabolite of Hypericum spp.

1
Institute of Biology and Ecology, Faculty of Science, Pavol Jozef Šafárik University in Košice, Šrobárova 2, 041 54 Košice, Slovakia
2
Central European Institute of Technology, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
3
National Centre for Biomolecular Research, Faculty of Science, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic
*
Author to whom correspondence should be addressed.
Academic Editors: Lisa M. Sedger and Heinrich Korner
Cancers 2021, 13(7), 1646; https://doi.org/10.3390/cancers13071646
Received: 17 December 2020 / Revised: 26 March 2021 / Accepted: 29 March 2021 / Published: 1 April 2021
(This article belongs to the Special Issue Tumor Necrosis Factor (TNF))
Hypoxic conditions are common in solid tumors and are very often connected with the poor prognosis of cancer patients. The lack of oxygen often causes the failure of therapy due to multiple mechanisms increasing cancer survival. Skyrin (SKR) is a secondary plant metabolite from the genus Hypericum spp., with a potential anticancer effects but still unknown mechanism of action. Based on our comprehensive analysis of SKR action, SKR shows significant efficiency against cancer, but not healthy cells, induces apoptosis, and upregulates Death receptor 5 in cancer cells in normoxic, as well as hypoxic conditions. SKR reverses TRAIL resistance even in TRAIL-resistant cancer cell lines in hypoxia. To sum up, SKR can be possibly used as a natural antitumor drug per se or as an adjuvant to TRAIL treatment in hypoxic and therapy-resistant tumors.
Skyrin (SKR) is a plant bisanthraquinone secondary metabolite from the Hypericum genus with potential use in anticancer therapy. However, its effect and mechanism of action are still unknown. The negative effect of SKR on HCT 116 and HT-29 cancer cell lines in hypoxic and normoxic conditions was observed. HCT 116 cells were more responsive to SKR treatment as demonstrated by decreased metabolic activity, cellularity and accumulation of cells in the G1 phase. Moreover, an increasing number of apoptotic cells was observed after treatment with SKR. Based on the LC-MS comparative proteomic data from hypoxia and normoxia (data are available via ProteomeXchange with the identifier PXD019995), SKR significantly upregulated Death receptor 5 (DR5), which was confirmed by real-time qualitative PCR (RT-qPCR). Furthermore, multiple changes in the Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-activated cascade were observed. Moreover, the reversion of TRAIL resistance was observed in HCT 116, HT-29 and SW620 cell lines, even in hypoxia, which was linked to the upregulation of DR5. In conclusion, our results propose the use of SKR as a prospective anticancer drug, particularly as an adjuvant to TRAIL-targeting treatment to reverse TRAIL resistance in hypoxia. View Full-Text
Keywords: skyrin; hypoxia; colorectal cancer; proteomics; Death receptor 5; TRAIL; TRAIL resistance; Hypericum skyrin; hypoxia; colorectal cancer; proteomics; Death receptor 5; TRAIL; TRAIL resistance; Hypericum
Show Figures

Figure 1

MDPI and ACS Style

Babinčák, M.; Jendželovský, R.; Košuth, J.; Majerník, M.; Vargová, J.; Mikulášek, K.; Zdráhal, Z.; Fedoročko, P. Death Receptor 5 (TNFRSF10B) Is Upregulated and TRAIL Resistance Is Reversed in Hypoxia and Normoxia in Colorectal Cancer Cell Lines after Treatment with Skyrin, the Active Metabolite of Hypericum spp. Cancers 2021, 13, 1646. https://doi.org/10.3390/cancers13071646

AMA Style

Babinčák M, Jendželovský R, Košuth J, Majerník M, Vargová J, Mikulášek K, Zdráhal Z, Fedoročko P. Death Receptor 5 (TNFRSF10B) Is Upregulated and TRAIL Resistance Is Reversed in Hypoxia and Normoxia in Colorectal Cancer Cell Lines after Treatment with Skyrin, the Active Metabolite of Hypericum spp. Cancers. 2021; 13(7):1646. https://doi.org/10.3390/cancers13071646

Chicago/Turabian Style

Babinčák, Marián, Rastislav Jendželovský, Ján Košuth, Martin Majerník, Jana Vargová, Kamil Mikulášek, Zbyněk Zdráhal, and Peter Fedoročko. 2021. "Death Receptor 5 (TNFRSF10B) Is Upregulated and TRAIL Resistance Is Reversed in Hypoxia and Normoxia in Colorectal Cancer Cell Lines after Treatment with Skyrin, the Active Metabolite of Hypericum spp." Cancers 13, no. 7: 1646. https://doi.org/10.3390/cancers13071646

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop